1574379-22-8

Basic information

• Product Name: 2-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)ethyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate
• Synonyms: 2-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)ethyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate
• CAS NO: 1574379-22-8
• Molecular Weight: 520.582
• Mol File: 1574379-22-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)ethyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)ethyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate(1574379-22-8)
• EPA Substance Registry System: 2-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)ethyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate(1574379-22-8)

Safety Data

• Hazardous Substances Data: 1574379-22-8(Hazardous Substances Data)

Upstream product

• 501-53-1 benzyl chloroformate 
• 100-39-0 benzyl bromide 
• 4940-11-8 2-ethyl-3-hydroxy-4-pyranone 
• 106-60-5 ALA 
• 5451-09-2 5-aminolevulinic acid hydrochloride 
• 112661-85-5 5-(benzyloxycarbonylamino)-4-oxopentanoic acid 
• 210244-51-2 1-[2'-(hydroxy)ethyl]-2-ethyl-3-benzyloxy-4(1H)-pyridinone 

Relevant articles and documents

Hydroxypyridinone and 5-Aminolaevulinic Acid Conjugates for Photodynamic Therapy

Photodynamic therapy (PDT) is a promising treatment strategy for malignant and nonmalignant lesions. 5-Aminolaevulinic acid (ALA) is used as a precursor of the photosensitizer, protoporphyrin IX (PpIX), in dermatology and urology. However, the effectiveness of ALA-PDT is limited by the relatively poor bioavailability of ALA and rapid conversion of PpIX to haem. The main goal of this study was to prepare and investigate a library of single conjugates designed to coadminister the bioactive agents ALA and hydroxypyridinone (HPO) iron chelators. A significant increase in intracellular PpIX levels was observed in all cell lines tested when compared to the administration of ALA alone. The higher PpIX levels observed using the conjugates correlated well with the observed phototoxicity following exposure of cells to light. Passive diffusion appears to be the main mechanism for the majority of ALA-HPOs investigated. This study demonstrates that ALA-HPOs significantly enhance phototherapeutic metabolite formation and phototoxicity.

PYRIDINONE COMPOUNDS FOR USE IN PHOTODYNAMIC THERAPY

A compound which is a compound of formula (I) or any salt thereof: wherein R1 is a Ci-C6 alkyl group, R2 is H or a Ci-C6 alkyl group, R3 is H or a Ci-C6 alkyl group, and n is an integer from 0 to 5.